Tumor-agnostic treatment treatments approved

 Tumor-agnostic treatment is a drug treatment that is used to treat any kind of cancer, regardless of where in the body it started or the type of tissue from which it developed. This type of treatment can be used when the tumor has a very specific molecular alteration that is targeted by the drug or predicts that the drug is likely to work.

Pembrolizumab was the first drug to be approved with a tumor-agnostic indication. Pembrolizumab is a type of immunotherapy, a drug that works by releasing the brakes on the immune system. In 2017, pembrolizumab was approved by the FDA to treat adults and children with solid tumors that have spread, called metastatic, or that cannot be treated with surgery, called unresectable. These tumors must also have a molecular alteration called microsatellite instability-high (MSI-H) or DNA mismatch repair deficiency (dMMR). Tumors that have MSI-H or dMMR have difficulty repairing damage to their DNA. As a result, they often develop large numbers of mutations in their DNA. These mutations produce abnormal proteins in the tumor cells that make it easier for immune cells to find and attack the tumor. 


In June 2020, the FDA approved another use for pembrolizumab to treat adults and children with unresectable or metastatic solid tumors that have a high tumor mutational burden

Most cancer treatments are developed to treat cancer that has developed in a specific organ or tissue, like breast cancer or lung cancer. A tumor-agnostic treatment treats any kind of cancer as long as cancer has the specific molecular alteration targeted by the drug.

Comments

Popular posts from this blog

Veterinary immunology protects vertebrates against pathogens

Phytochemistry is the study of plant compounds quality during manufacture

Immunomodulators are medicines that can support the vulnerable function